Terry Kohler - 16 Jul 2021 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
Chief Financial Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
VRCA
Transactions as of
16 Jul 2021
Net transactions value
$0
Form type
4
Filing time
20 Jul 2021, 18:04:23 UTC
Next filing
25 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Employee Stock Option (right to buy) Award $0 +125,000 $0.000000 125,000 16 Jul 2021 Common Stock 125,000 $10.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the total shares subject to the option shall vest on July 16, 2022 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.